Biosergen: Phase II studies and share price triggers hopefully just around the corner

Biosergen investeringscase

Biosergen’s H1-2022 report and major shareholder loan to the company point to more share price triggers this year and ahead of product launch and thus potential for new positive share price development.

Biosergen: Ticker: BIOSGN | Price: SEK 5,11 | Market Cap.: SEK 141M | YTD price development: -5,72%

Biosergen is a biotech company listed on Nasdaq First North Sweden in June 2021. The company is developing an innovative drug to treat fungal infections that kill 1.5 million people annually – in both industrialised and third world countries.

The company’s BSG005 medical drug has demonstrated significant safety data and potency advantages over existing products developed in the 1950s-70s. BSG005 is in clinical phase I (the first of three phases of development towards the market launch), from which positive data have emerged. The first of several drugs is expected to be on the market in 2026/27.

Read the full investment case on Biosergen here

H1 and support from the main shareholder

Biosergen has followed the planned development of BSG005, which has enrolled the third group of subjects in the phase l trial. However, the company’s share price, although outperforming the healthcare sector, has not developed positively and therefore no capital was raised from warrants issued at the time of the IPO.

Biosergen’s cash balance at the end of June 2022 was mSEK 5.7 and with cash flow from operations for the half year of mSEK -25, the company needs to raise capital to fund ongoing and future studies. As bridge financing, Biosergens’ main shareholder Östersjöstiftelsen (43.2% of the shares) has provided the company with a convertible loan of mSEK 7.0. The loan, which matures in December 2023 and carries an interest rate of 8% p.a., will finance the company’s development this year.

Biosergen’s pipeline

Phase l study and potential share price triggers

The preliminary positive results from the phase I study (in healthy subjects) of BSG005 indicate that the fungicide is not harmful to humans and that therefore one can look towards increasing the dose and towards phase II studies where the patient group will be expanded and the correct dosage clarified.

The stock has often responded positively to the Phase I study, including the enrolment of a new group of subjects. There will be continuous news from the phase l study, so there will be continuous opportunities for price triggers until spring.

If Biosergen continues the positive development of BSG005, we expect the company to make a capital increase on the back of positive news and thus potentially at a higher share price than the current and almost historically low price level.

YTD share price development versus Kapital Partner Healthcare Index

Printervenlig version af artiklen.

Would you like to receive one of our newsletters? Please fill the form below. (Newsletters are in danish)

  • Investment cases  – Newsletters with current investment cases from the Nordic growth exchanges and the life science sector.
  • IPOs – Updates on new and ongoing IPOs in Scandinavia and their results. (Newsletter from Nyemission.dk)
  • News – News from and about Kapital Partner, including insight into the capital markets and stock exchange listings as well as invitations to investor meetings and events.

*If you want information about our upcoming investment association with a focus on the Nordic growth exchanges, including the opportunity to invest, sign up for the newsletter. Nyheder.



Investor network:

Do you want to be part of Kapital Partner’s investor network, where you get access to investments in companies and issues, as well as invitations to investor-oriented events,
please fill out the form in here.

Tilmeld Dig Kapital Partners Investeringscases

Investeringscases er udarbejdet af Kapital Partners analyseteam. Vi udarbejder investeringscases på selskabs-, markeds- og sektor-niveau.

Del indlægget på sociale media eller på email. 

LinkedIn
Facebook
Twitter
Email